Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03490669 |
Recruitment Status :
Terminated
(Safety and PK/PD data from Dose Escalation support further development; Dose Expansion canceled)
First Posted : April 6, 2018
Last Update Posted : January 6, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This is a 2-part study to evaluate the safety and antitumor activity of MSC-1. MSC-1 is a first-in-class, humanized monoclonal antibody (IgG1) which binds to the immunosuppressive human cytokine Leukemia Inhibitory Factor (LIF), and is intended to treat adult patients with Advanced Solid Tumors.
In part 1, multiple dose levels of MSC-1 in patients with Advanced Solid Tumors will be studied to determine the recommended dose for further evaluation of safety and efficacy in Part 2.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Advanced Solid Tumors Pancreatic Cancer Non Small Cell Lung Cancer Ovarian Cancer | Biological: MSC-1 | Phase 1 |
MSC-1 is a first-in-class, humanized monoclonal antibody (IgG1) which binds to the immunosuppressive human cytokine Leukemia Inhibitory Factor (LIF), and is intended to treat adult patients with advanced solid tumors. LIF is a pleiotropic cytokine involved in many physiological and pathological processes including the promotion of an immunosuppressive environment. In cancer, it is hypothesized that LIF expressing malignancies co-opt this activity, creating an immunosuppressive tumor microenvironment as well as promoting the activity of cancer-initiating cell(s) (CICs). LIF is highly expressed in a subset of tumors across multiple solid tumor types.
During dose escalation, patients with Advanced Solid Tumors will be treated with MSC-1 with the primary objective of determining the safety and tolerability of MSC-1 and defining an appropriate dose for further evaluation in dose expansion. MSC-1 will be administered intravenously (IV) until disease progression, unmanageable toxicity, withdrawal of consent or study termination.
In dose expansion, up to 4 parallel cohorts of patients with LIF-High tumors (NSCLC, Ovarian Cancer, Pancreatic Cancer), and a cohort of mixed Solid Tumors (referred to as the "basket cohort"), may be treated at the recommended expansion dose to further characterize the safety, tolerability, PK, PD and anti-tumor activity of MSC-1.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 41 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Intervention Model Description: | Open-Label |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MSC-1 in Patients With Advanced Solid Tumors |
Actual Study Start Date : | May 11, 2018 |
Actual Primary Completion Date : | September 23, 2019 |
Actual Study Completion Date : | September 23, 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Dose Escalation
Multiple dose levels of MSC-1 treatment once every 3 weeks
|
Biological: MSC-1
humanized monoclonal antibody for intravenous administration |
Experimental: Dose Expansion
MSC-1 treatment at the recommended Phase 2 dose once every 3 weeks
|
Biological: MSC-1
humanized monoclonal antibody for intravenous administration |
- Evaluate the safety and tolerability of MSC-1 and determine the recommended dose for MSC-1 monotherapy for further evaluation in the expansion part of the study. [ Time Frame: Patients will be evaluated for approximately 6 months or until disease progression ]Assessment of frequency & severity of adverse events
- Assess the preliminary anti-tumor activity of MSC-1 monotherapy [ Time Frame: Patients will be evaluated for approximately 6 months or until disease progression ]Determine objective response rate (ORR)
- Confirm safest dose of MSC-1 for further study [ Time Frame: Patients will be evaluated for approximately 6 months or until disease progression ]Assessment of adverse events
- Characterize the PK of MSC-1 [ Time Frame: Patients will be evaluated before and after each dose of MSC-1 for approximately 6 months or until disease progression. PK will be evaluated more frequently for the first 2 cycles of treatment. ]Serum levels of MSC-1

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria (All patients):
- Confirmed Advanced Unresectable Solid Tumor
- Measurable disease by RECIST 1.1 by CT or MRI
- Documented disease progression on or following last line of therapy
- Archival tumor sample for submission
- ECOG performance status 0 or 1
- Resolution of all acute, reversible toxic effects of prior therapy or surgical procedures to at least grade 1 (except alopecia and peripheral neuropathy to at least grade 2)
- Adequate organ function
- A limited number of patients enrolled in Dose Escalation may be required to agree to pre- and on-treatment tumor biopsies
Inclusion Criteria (Dose Expansion patients only)
- LIF- High NSCLC, Ovarian Cancer, or Pancreatic Cancer for the tumor-specific cohorts or Advanced Solid Tumor for the basket cohort as assessed by tumor tissue evaluation by IHC
- All patients enrolled in Dose Expansion must agree to undergo pre- and on-treatment tumor biopsies
Exclusion Criteria (All Patients):
- Systemic anti-cancer therapy within 4 weeks or 5 half-lives prior to study entry
- Previous or concurrent malignancy that could affect compliance with protocol or interpretation of results
- Clinically significant, unstable cardiovascular or pulmonary disease as specified in detail in the study protocol
- History of acquired or congenital immunodeficiency syndrome or receiving immunosuppressive therapy
- Uncontrolled infections or serologically positive HIV or hepatitis B or C infection
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase risk associated with study participation or interfere with interpretation of study results

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03490669
United States, Arizona | |
HonorHealth | |
Scottsdale, Arizona, United States, 85258 | |
United States, Michigan | |
START MidWest | |
Grand Rapids, Michigan, United States, 49546 | |
United States, New Jersey | |
Memorial Sloan Kettering Cancer Center- Monmouth | |
Middletown, New Jersey, United States, 07748 | |
United States, New York | |
Memorial Sloan Kettering Cancer Center- Westchester | |
Harrison, New York, United States, 10604 | |
Memorial Sloan Kettering Cancer Center | |
New York, New York, United States, 10065 | |
Canada, Ontario | |
Princess Margaret Cancer Center | |
Toronto, Ontario, Canada, M5G 1Z5 | |
Spain | |
Hospital Universitario Vall d'Hebron | |
Barcelona, Spain, 08035 |
Study Director: | Robert Wasserman, MD | Northern Biologics |
Responsible Party: | Northern Biologics Inc. |
ClinicalTrials.gov Identifier: | NCT03490669 |
Other Study ID Numbers: |
MSC-1-101 |
First Posted: | April 6, 2018 Key Record Dates |
Last Update Posted: | January 6, 2020 |
Last Verified: | January 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |